Sedec Therapeutics
Natick, Massachusetts, United States
About Sedec Therapeutics
Targeting novel protein acylation pathways for treating inflammatory and autoimmune diseases
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Funding stage: Seed
- Last round: Seed (Jan 2023)
- Website: sedectx.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/sedec-therapeutics-2574479 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.